SURFIRE-VT: Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia

Sponsor
Rush University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05618717
Collaborator
(none)
150
1
72
2.1

Study Details

Study Description

Brief Summary

Vistag SurPoint is a proprietary module that generates a numerical tag index which can be used as multiparametric lesion quality marker to guide ablation in the clinical setting for ablation of atrial arrhythmias. SurPoint tag index has studied to guide ablation of ventricular arrhythmias, such as premature ventricular complexes, but its effectiveness and safety for ablation of Ventricular Tachycardia in patient with Ischemic and Non-Ischemic Cardiomyopathies is not well established.

In this single center prospective observation registry, a ventricular ablation strategy utilizing radiofrequency delivery duration cut off determined by a maximum Surpoint index value of 550 will be compared to conventional operator determined duration of radiofrequency delivery based on combination of time (i.e. 30, 60, 90, and 120 seconds), magnitude of impedance drop, attenuation of abnormal electrograms, and achieving non-capture with high-output pacing after ablation.

The Surpoint Tag Index Ablation group will be matched with a control group of patients undergoing VT ablation using the conventional time-based radiofrequency strategy and the patients in this group will be selected using propensity matching based on relevant baseline patient and clinical characteristic variables.

Primary outcomes of interest: Recurrence of sustained ventricular tachycardia or Internal Cardiac Defibrillator Therapy.

Secondary outcomes of interest: Hospitalization for ventricular tachycardia, repeat ablation procedures, all-cause mortality, acute procedural complications, rate of steam pops during ablation procedures

Follow up: Up to 24 months after ablation procedure. Follow up will be obtained by office visits and device interrogation reports.

Condition or Disease Intervention/Treatment Phase
  • Device: Radiofrequency Ablation

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
150 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia in Patients With Ischemic and Non-Ischemic Cardiomyopathy
Actual Study Start Date :
Jan 1, 2018
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Surpoint Index Guided Ablation Group

Maximum Radiofrequency delivery duration cannot exceed Surpoint Index of 550

Device: Radiofrequency Ablation
Radiofrequency Ablation using irrigated ablation catheter

Conventional Ablation Group

Operator determined ablation duration regardless of Surpoint Index Value

Device: Radiofrequency Ablation
Radiofrequency Ablation using irrigated ablation catheter

Outcome Measures

Primary Outcome Measures

  1. Recurrence Event of Sustained Ventricular Tachycardia or ICD therapy [2 years]

    Composite outcome of sustained ventricular tachycardia (episode lasting > 30 seconds detected by ICD) or ventricular tachycardia episode treated successfully by ICD therapy (Including ventricular tachycardia episodes terminated by ATP or ICD shock in < 30 seconds based programmed detection/treatment ICD settings)

Secondary Outcome Measures

  1. Hospitalization for Ventricular Tachycardia [2 yearr]

    Outcome of hospitalization for primary admission diagnosis of ventricular tachycardia with or without ICD treatment

  2. All-Cause Mortality [2 years]

    Outcome of death after ablation procedure from cardiovascular or non-cardiovascular cause

  3. Redo Ventricular Tachycardia Ablation Procedure [2 years]

    Outcome of repeat ablation procedure for sustained ventricular tachycardia or appropriate ICD therapy after index ventricular tachycardia ablation procedure

  4. Procedural Complications [7 days]

    Outcome of rate of complications with 7 days of ventricular tachycardia ablation procedure including but not limited to bleeding, death, pericardial effusion, cardiac tamponade, stroke, arterial thromboemblism, steam pops, thrombus formation, cardiogenic shock, phrenic nerve paralysis, congestive heart failure)

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Structural Heart Disease: Ischemic or Non-Ischemic Cardiomyopathy

  • Sustained Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation

Exclusion Criteria:
  • If clinical ventricular arrhythmia is predominantly PVCs, polymorphic ventricular tachycardia, or ventricular fibrillation

  • Myocardial infarction or Cardiac Surgery within 6 months

  • Severe mitral regurgitation

  • Stroke or TIA within 6 months

  • Prior Ventricular Tachycardia Ablation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Henry Huang Chicago Illinois United States 60657

Sponsors and Collaborators

  • Rush University Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Henry Huang, Primary Investigator, Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT05618717
Other Study ID Numbers:
  • 21011101
First Posted:
Nov 16, 2022
Last Update Posted:
Nov 16, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 16, 2022